Aim 1: Confirmation of ERCC1 biomaker of chemoresistance
This study will confirm that patients who respond well (long-term) to chemotherapy, have higher levels of the protein ERCC1 in their tumours after chemotherapy, compared to patients who relapse. We will also collect data on the cellular location of another protein called XPC that detects when chemotherapy has damaged the cell’s DNA. We have some preliminary data indicating that XPC is not in the correct location within ovarian cancer cells that have become chemoresistant. This project will build on local, national and international collaborations – Australian Ovarian Cancer Study (Prof Anna DeFazio, Westmead), Prof Deborah Marsh and Prof Anthony Gill (USydney) and Dr Sherry Wu and Prof. Anil Sood (MD Anderson, Texas).
Aim 2: Investigate the epigenome of ovarian cancer extreme responders and non-responders to platinum chemotherapy
This study will involve sequencing the genome and epigenome of ovarian cancers from patient that have extremely good response and extremely poor response to platinum chemotherapy. Once the differences are identified we can target the poor responders genome/epigenome with targeted therapies to make them more like the extreme responders genome/epigenome. This data will form the background required to develop clinical trials targeting genome and epigenome changes. This project is a collaboration between local and national researchers including Dr Jim Scurry (pathology), Drs Ken Jaaback, Geoof Otton, Yvette Ius and Rachel O’Sullivan (Gynacology surgical oncology), Dr Janine Lombard (Medical oncology), Prof Deborah Marsh (Kolling Institute/USyd) and Prof Sue Clark (Garvan Institute)